{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28Cohort+B%29&page=15",
    "query": {
      "intervention": "Placebo (Cohort B)",
      "page": 15
    },
    "page_size": 10
  },
  "pagination": {
    "page": 15,
    "page_size": 10,
    "total_count": 425,
    "total_pages": 43,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28Cohort+B%29&page=16&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28Cohort+B%29&page=14&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T06:09:59.748Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01818011",
      "title": "A Three-part Study to Determine the Safety, Tolerability and Pharmacokinetics of GSK1322322 in Healthy Volunteers and Healthy Male Japanese Subjects",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Infections, Bacterial"
      ],
      "interventions": [
        {
          "name": "GSK1322322 Initial fit for purpose tablets",
          "type": "DRUG"
        },
        {
          "name": "GSK1322322 over granulated tablets",
          "type": "DRUG"
        },
        {
          "name": "GSK1322322 intended commercial tablets",
          "type": "DRUG"
        },
        {
          "name": "Placebo tablets",
          "type": "DRUG"
        },
        {
          "name": "13C-GSK1322322 stable isotope powder",
          "type": "DRUG"
        },
        {
          "name": "GSK1322322 for injection",
          "type": "DRUG"
        },
        {
          "name": "Placebo injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 12,
      "start_date": "2013-08-07",
      "completion_date": "2013-10-18",
      "has_results": false,
      "last_update_posted_date": "2019-01-15",
      "last_synced_at": "2026-10-14T06:09:59.748Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01818011"
    },
    {
      "nct_id": "NCT04228783",
      "title": "A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ebola"
      ],
      "interventions": [
        {
          "name": "Ad26.ZEBOV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MVA-BN-Filo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Janssen Vaccines & Prevention B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 974,
      "start_date": "2020-02-18",
      "completion_date": "2022-04-25",
      "has_results": true,
      "last_update_posted_date": "2025-05-25",
      "last_synced_at": "2026-10-14T06:09:59.748Z",
      "location_count": 7,
      "location_summary": "Mobile, Alabama • Tempe, Arizona • Lexington, Kentucky + 4 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04228783"
    },
    {
      "nct_id": "NCT01670266",
      "title": "Single and Multiple Dose Escalation and Two-sequence Crossover Study of ONO-9054 in Patients With Ocular Hypertension or Mild Open-angle Glaucoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ocular Hypertension (OHT)",
        "Mild Open Angle-glaucoma (OAG)"
      ],
      "interventions": [
        {
          "name": "ONO-9054",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ono Pharma USA Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 60,
      "start_date": "2012-08",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-06-03",
      "last_synced_at": "2026-10-14T06:09:59.748Z",
      "location_count": 3,
      "location_summary": "Costa Mesa, California • Newport Beach, California • Santa Ana, California",
      "locations": [
        {
          "city": "Costa Mesa",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Santa Ana",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01670266"
    },
    {
      "nct_id": "NCT01448824",
      "title": "A Study of LY2484595 on Pharmacokinetics in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "LY2484595",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Ketoconazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 82,
      "start_date": "2011-10",
      "completion_date": "2012-02",
      "has_results": true,
      "last_update_posted_date": "2019-04-02",
      "last_synced_at": "2026-10-14T06:09:59.748Z",
      "location_count": 2,
      "location_summary": "Daytona Beach, Florida • Dallas, Texas",
      "locations": [
        {
          "city": "Daytona Beach",
          "state": "Florida"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01448824"
    },
    {
      "nct_id": "NCT05747924",
      "title": "Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "FSHD",
        "FSHD1",
        "FSHD2",
        "FMD",
        "FMD2",
        "Fascioscapulohumeral Muscular Dystrophy",
        "Fascioscapulohumeral Muscular Dystrophy Type 1",
        "Fascioscapulohumeral Muscular Dystrophy Type 2",
        "Dystrophies, Facioscapulohumeral Muscular",
        "Dystrophy, Facioscapulohumeral Muscular",
        "Facioscapulohumeral Muscular Dystrophy 1",
        "Facioscapulohumeral Muscular Dystrophy 2",
        "Facio-Scapulo-Humeral Dystrophy",
        "Atrophy, Facioscapulohumeral",
        "Atrophies, Facioscapulohumeral",
        "Facioscapulohumeral Atrophy",
        "Muscular Dystrophies",
        "Muscular Dystrophy, Facioscapulohumeral",
        "FSH Muscular Dystrophy",
        "Landouzy Dejerine Dystrophy",
        "Landouzy-Dejerine Muscular Dystrophy",
        "Dystrophies, Landouzy-Dejerine",
        "Dystrophy, Landouzy-Dejerine",
        "Landouzy-Dejerine Syndrome",
        "Muscular Dystrophy, Landouzy Dejerine",
        "Progressive Muscular Dystrophy",
        "FSH"
      ],
      "interventions": [
        {
          "name": "AOC 1020",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Avidity Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "16 Years to 70 Years"
      },
      "enrollment_count": 90,
      "start_date": "2023-04-04",
      "completion_date": "2026-03-20",
      "has_results": false,
      "last_update_posted_date": "2026-07-16",
      "last_synced_at": "2026-10-14T06:09:59.748Z",
      "location_count": 14,
      "location_summary": "Los Angeles, California • Palo Alto, California • San Diego, California + 11 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05747924"
    },
    {
      "nct_id": "NCT06026397",
      "title": "A Sequential Single and Multiple Ascending Dose (SAD/MAD) Study of SK10 Powders in Healthy Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chemotherapy-induced Diarrhea"
      ],
      "interventions": [
        {
          "name": "SK10",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Guangzhou Zhiyi Biotechnology Co., Ltd.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 24,
      "start_date": "2023-08-01",
      "completion_date": "2024-02-11",
      "has_results": false,
      "last_update_posted_date": "2024-02-20",
      "last_synced_at": "2026-10-14T06:09:59.748Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06026397"
    },
    {
      "nct_id": "NCT01357213",
      "title": "Phase 1 PK Study of XOMA 3AB",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Botulism"
      ],
      "interventions": [
        {
          "name": "XOMA 3AB",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 24,
      "start_date": "2011-05",
      "completion_date": "2013-05",
      "has_results": false,
      "last_update_posted_date": "2014-12-05",
      "last_synced_at": "2026-10-14T06:09:59.748Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01357213"
    },
    {
      "nct_id": "NCT03547206",
      "title": "Efficacy & Safety of RPh201 Treatment in Patients With Previous Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Nonarteritic Anterior Ischemic Optic Neuropathy"
      ],
      "interventions": [
        {
          "name": "RPh201 Cohort A",
          "type": "DRUG"
        },
        {
          "name": "Placebo Cohort A",
          "type": "OTHER"
        },
        {
          "name": "RPh201 Cohort B",
          "type": "DRUG"
        },
        {
          "name": "Placebo Cohort B",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Regenera Pharma Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 165,
      "start_date": "2018-07-10",
      "completion_date": "2020-09-27",
      "has_results": false,
      "last_update_posted_date": "2020-10-12",
      "last_synced_at": "2026-10-14T06:09:59.748Z",
      "location_count": 15,
      "location_summary": "Palo Alto, California • Pasadena, California • Orange, Connecticut + 12 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "Connecticut"
        },
        {
          "city": "Waterbury",
          "state": "Connecticut"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03547206"
    },
    {
      "nct_id": "NCT02724085",
      "title": "A Phase 1 Study to Assess the Safety, Tolerability and PK of IV TP-271",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pneumonia"
      ],
      "interventions": [
        {
          "name": "TP-271",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tetraphase Pharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 57,
      "start_date": "2015-12-18",
      "completion_date": "2016-12-12",
      "has_results": false,
      "last_update_posted_date": "2021-12-13",
      "last_synced_at": "2026-10-14T06:09:59.748Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02724085"
    },
    {
      "nct_id": "NCT06538558",
      "title": "Study to Assess the Use of Tezampanel for Opioid Withdrawal Syndrome in Treatment-Seeking Patients With Opioid Use Disorder",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Opioid Use Disorder"
      ],
      "interventions": [
        {
          "name": "Tezampanel",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Proniras Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 40,
      "start_date": "2024-10-16",
      "completion_date": "2027-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-17",
      "last_synced_at": "2026-10-14T06:09:59.748Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06538558"
    }
  ]
}